公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2020 | Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection | Cheng X.; Uchida T.; Xia Y.; Umarova R.; CHUN-JEN LIU ; PEI-JER CHEN ; Gaggar A.; Suri V.; Mücke M.M.; Vermehren J.; Zeuzem S.; Teraoka Y.; Osawa M.; Aikata H.; Tsuji K.; Mori N.; Hige S.; Karino Y.; Imamura M.; Chayama K.; Liang T.J. | Journal of Clinical Investigation | 40 | 36 | |
2020 | Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial | Spinner C.D.; Gottlieb R.L.; Criner G.J.; Arribas López J.R.; Cattelan A.M.; Soriano Viladomiu A.; Ogbuagu O.; Malhotra P.; Mullane K.M.; Castagna A.; Chai L.Y.A.; Roestenberg M.; Tsang O.T.Y.; Bernasconi E.; Le Turnier P.; SHAN-CHWEN CHANG ; Sengupta D.; Hyland R.H.; Osinusi A.O.; Cao H.; Blair C.; Wang H.; Gaggar A.; Brainard D.M.; McPhail M.J.; Bhagani S.; Ahn M.Y.; Sanyal A.J.; Huhn G.; Marty F.M. | JAMA - Journal of the American Medical Association | 872 | 818 | |
2021 | Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease | Chuang W.-L.; Hu T.-H.; Buggisch P.; Moreno C.; Su W.-W.; Biancone L.; Camargo M.; Hyland R.; Lu S.; Kirby B.J.; Dvory-Sobol H.; Osinusi A.; Gaggar A.; Peng C.-Y.; CHEN-HUA LIU ; Sise M.E.; Mangia A. | The American journal of gastroenterology | 7 | 6 | |
2020 | Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials | Asahina Y.; CHUN-JEN LIU ; Gane E.; Itoh Y.; Kawada N.; Ueno Y.; Youn J.; Wang C.-Y.; Llewellyn J.; Matsuda T.; Gaggar A.; Mo H.; Dvory-Sobol H.; Crans G.; Chuang W.-L.; PEI-JER CHEN ; Enomoto N. | Hepatology Research | 6 | 6 |